EMCUREEmcure Pharmaceuticals Limited Forensic Risk Analysis
Financial profile remains stable for now. Weakness is detected in balance sheet stress. No immediate concerns are visible. Risk is gradually increasing.
Score WaterfallAbsolute contribution points of each forensic pillar to the final risk score. Derived from: Sector Baseline + Active Penalties - Mitigation Buffers.
Investment Risk Thesis
Current risk score has risen from 0 → 8 over 12 quarters.
- Inventory Stress
- Working Capital Expansion
- Inventory turnover
- Working capital efficiency
Active Risk Objects (2)
"Stock is piling up in the warehouse. Inventory turnover is slowing down dangerously."
"Early signs of working capital expansion. Receivable or inventory days are creeping up."
Correlation AnalysisVisualizing the relationship between stock price movement and structural risk objects.
The structural architecture is currently robust. Capital resilience buffers in balance sheet stress remain well-maintained against forensic benchmarks. Systematic scans of core structural metrics confirm the absence of material structural stress. The current structural trajectory supports a stable risk outlook.
Stage 2 — Advancing
The company is in a growth phase. Institutional sentiment is highly positive, supported by strong fundamentals and sustained risk reduction.
PEER COMPARISON
Ranked comparison against sector peers
Stable
Stable
Stable
Watch
* Peer comparison is based on risk signals, not valuation or returns.
Risk Profiles
Deterioration Timeline
Working Capital Expansion
Inventory Stress
Inventory Stress
Working Capital Expansion
Working Capital Expansion